• 1
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States,. 1988–2000. JAMA. 2003;290:199206.
  • 2
    Bramlage P, Pittrow D, Hans-Ulrich W, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904910.
  • 3
    Riehle JF, Lackland DT, Okonofua EC, et al. Ethnic differences in the treatment and control of hypertension in patients with diabetes. J Clin Hypertens. 2005;7:445454.
  • 4
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393404.
  • 5
    Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594599.
  • 6
    Lloyd-Jones DM, Evans JC, Larson MG, et al. Treatment and control of hypertension in the community: a prospective analysis. Hypertension. 2002;40:640646.
  • 7
    Caro JJ, Speckman JL, Salas M. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:4146.
  • 8
    Brown MA, Buddle ML. Martin. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:12631269.
  • 9
    Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension. 2005;46:10531059.
  • 10
    Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712718.
  • 11
    Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;45:10351041.
  • 12
    He JF, Markandu ND, MacGregor GA. Modest salt reduction lowers blood pressure in isolated systolic hypertension and combined hypertension. Hypertension. 2005;46:6670.
  • 13
    Wing LM, Arnolda LF, Harvey PJ, et al. Low-dose diuretic and/or dietary sodium restriction when blood pressure is resistant to ACE inhibitor. Blood Press. 1998;7:299307.
  • 14
    Singer DR, Markandu ND, Sugden AL, et al. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension. 1991;17:798803.
  • 15
    Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604608.
  • 16
    Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46:500507.
  • 17
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? Ann Intern Med. 1994;121:289300.
  • 18
    Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107:628635.
  • 19
    Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension. 2000;36:461465.
  • 20
    White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929934.
  • 21
    Wildman RP, Gu D, Muntner P, et al. Alcohol intake and hypertension subtypes in Chinese men. J Hypertens. 2005;23:737743.
  • 22
    de Gaudemaris R, Lang T, Chatellier G, et al. Socioeconomic inequalities in hypertension: prevalence and care: the IHPAF study. Hypertension. 2002;39:11191125.
  • 23
    Radi S, Lang T, Lauwers-Cancès V, et al. One-year hypertension incidence and its predictors in a working population: the IHPAF study. J Human Hypertens. 2004;18:487494.
  • 24
    Aguilera MT, de la Sierra A, Coca A, et al. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension. 1999;33:653657.
  • 25
    Nieto FJ, Young TB, Lind BK, et al., For the Sleep Heart Health Study. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA. 2000;283:18291836.
  • 26
    Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:13781384.
  • 27
    Lavie P, Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep. 2001;24:721725.
  • 28
    Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens. 2001;19:22712277.
  • 29
    Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003;107:6873.
  • 30
    Logan AG, Tkacova R, Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J. 2003;21:241247.
  • 31
    Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892896.
  • 32
    Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699705.
  • 33
    Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:22172226.
  • 34
    Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125:112117.
  • 35
    Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catherization. J Am Soc Nephrol. 1992;2:16081616.
  • 36
    Rihal CS, Textor SC, Breen JF, et al. Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc. 2002;77:309316.
  • 37
    Birrer M, Do DD, Mahler F, et al. Treatment of renal artery fibromuscular dysplasia with ballon angioplasty: a prospective follow-up study. Eur J Vasc Endovasc Surg. 2002;23:146152.
  • 38
    Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982988.
  • 39
    Garg JP, Elliott WJ, Folker A, et al., For the RUSH Hypertension Service. Resistant hypertension revisted: a comparison of 2 university-based cohorts. Am J Hypertens. 2005;18:619626.
  • 40
    Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925930.
  • 41
    Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709716.
  • 42
    Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:11481155.